Tessera Therapeutics

Tessera Therapeutics is a Flagship Pioneering-incubated biotech developing a proprietary 'Gene Writing' platform, which it positions as a new category of genetic medicine beyond traditional gene editing and therapy. The technology is designed to make both small and large, permanent genomic alterations and is coupled with a non-viral delivery system. The company has advanced its lead in vivo program, TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD), into clinical development, with FDA Fast Track and Orphan Drug designations, and is also pursuing an HIV cure with grant support. As a private, pre-revenue company, Tessera is focused on translating its platform into potentially curative therapies for major unmet medical needs.

Gene Writing™, a platform designed to make precise, permanent small and large alterations to the human genome, coupled with non-viral delivery technology.

Tessera competes in the advanced genetic medicine space against CRISPR-based editing companies (e.g., CRISPR Therapeutics, Intellia Therapeutics), base editing firms (e.g., Beam Therapeutics), and viral gene therapy developers. Its differentiation hinges on the claimed advantages of Gene Writing—particularly for large DNA insertions—and its non-viral delivery system, but it must demonstrate these advantages clinically.